As we continue to honor GBM Awareness Day, Plus Therapeutics is proud to spotlight new insights from our RESPECT-GBM Phase 2 clinical trial—research aimed at addressing the urgent need for better treatment options for patients with recurrent glioblastoma (GBM).
In a recently released video interview with Cancer Network, Andrew Brenner, M.D., Ph.D., one of the Principal Investigators of the RESPECT-GBM trial and neuro-oncologist at UT Health San Antonio, shared a significant finding from the study:
Patients who received an absorbed dose of greater than 100 Gy of REYOBIQ™ (rhenium Re186 obisbemeda) achieved a median overall survival of 17 months—a notable result in the treatment of recurrent GBM, where survival rates are often limited.
This outcome highlights the potential therapeutic benefit of REYOBIQ™, an investigational targeted radiotherapy, which is being delivered directly to the tumor site via convection-enhanced delivery (CED). The trial is part of Plus Therapeutics’ broader strategy to develop precision radiotherapeutics for central nervous system cancers.
Watch the new video clip featuring Dr. Brenner here:
View Interview on Cancer Network
Join the RESPECT-GBM Clinical Trial
The RESPECT-GBM Phase 2 trial is actively enrolling patients. If you or a loved one is facing recurrent glioblastoma, you may be eligible to participate in this study and help advance the next generation of cancer treatments.
Learn more and check eligibility at:
respect-trials.com/gbm
Or email our team at: respect@plustherapeutics.com
#GBMAwarenessDay #Glioblastoma #GBM #BrainCancer #REYOBIQ #RESPECTGBM #Radiotherapeutics #ClinicalTrials #NeuroOncology #CancerResearch #PSTV #OncologyInnovation #TargetedTherapy #CED #PlusTherapeutics
Recent Comments